Compare Adaptive Biotechnologies Corp (ADPT) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sony Group Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Sony Group Corp trades at $21.18 (market cap $127.11B). The key difference: Sony Group Corp is far larger — about 38.2× Adaptive Biotechnologies Corp's market cap, and Sony Group Corp pays a 0.74% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SONY | |
|---|---|---|
Market Cap | $3.33B | $127.11B |
Sector | Health | Technology |
52-Week High | $22.37 | $30.26 |
52-Week Low | $10.24 | $19.32 |
Enterprise Value | $3.19B | $123.60B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Sony's stock trades at $21.40, up 2.93% today, with a bullish technical signal from moving averages. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong 2025 revenue of $12.96 trillion and net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive, with 68.75% recommending buy. Recent news highlights Sony's shift to digital-only game discs by 2028, sparking consumer backlash.
The outlook is cautiously optimistic due to strong analyst support and solid cash flow, but risks include the negative profit margin forecast for 2026 and market reaction to the digital transition. Investors should weigh the company's innovation efforts against execution risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
